EP2929041A4 - PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE - Google Patents

PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE

Info

Publication number
EP2929041A4
EP2929041A4 EP13861394.8A EP13861394A EP2929041A4 EP 2929041 A4 EP2929041 A4 EP 2929041A4 EP 13861394 A EP13861394 A EP 13861394A EP 2929041 A4 EP2929041 A4 EP 2929041A4
Authority
EP
European Patent Office
Prior art keywords
omega
associated methods
acid compositions
pentaenoic acid
pentaenoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13861394.8A
Other languages
German (de)
French (fr)
Other versions
EP2929041A1 (en
Inventor
George Bobotas
Abdel Aziz Fawzy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Priority to EP21170003.4A priority Critical patent/EP3888646A1/en
Publication of EP2929041A1 publication Critical patent/EP2929041A1/en
Publication of EP2929041A4 publication Critical patent/EP2929041A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B20/00—Preservation of edible oils or fats
    • A23B20/30—Preservation of other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B5/00—Preserving by using additives, e.g. anti-oxidants
    • C11B5/0007—Organic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
EP13861394.8A 2012-12-06 2013-12-06 PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE Withdrawn EP2929041A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21170003.4A EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734331P 2012-12-06 2012-12-06
US201361780948P 2013-03-13 2013-03-13
PCT/US2013/073701 WO2014089501A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP21170003.4A Division EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Publications (2)

Publication Number Publication Date
EP2929041A1 EP2929041A1 (en) 2015-10-14
EP2929041A4 true EP2929041A4 (en) 2016-06-08

Family

ID=50884050

Family Applications (3)

Application Number Title Priority Date Filing Date
EP13861305.4A Withdrawn EP2928462A4 (en) 2012-12-06 2013-12-06 METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID
EP13861394.8A Withdrawn EP2929041A4 (en) 2012-12-06 2013-12-06 PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE
EP21170003.4A Withdrawn EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP13861305.4A Withdrawn EP2928462A4 (en) 2012-12-06 2013-12-06 METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP21170003.4A Withdrawn EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Country Status (9)

Country Link
EP (3) EP2928462A4 (en)
JP (4) JP2016501249A (en)
KR (3) KR20150103671A (en)
CN (4) CN112107570A (en)
AU (7) AU2013354979A1 (en)
CA (2) CA2894366A1 (en)
IN (2) IN2015DE05009A (en)
MX (2) MX2015007085A (en)
WO (2) WO2014089501A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101568665B1 (en) 2015-07-21 2015-11-12 디와이오토 주식회사 Brush structure for increasing ripple current of motor
EP3475704A1 (en) * 2016-06-28 2019-05-01 Nestec S.A. Biomarkers of blood-brain barrier dysfunction
JP2018168139A (en) * 2016-10-21 2018-11-01 マルハニチロ株式会社 Composition for reducing or increasing neutral fat value containing n-3 unsaturated fatty acid, and use of n-3 unsaturated fatty acid in the production of the composition
JP7099821B2 (en) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 PCSK9 inhibitor and food composition for improving cholesterol metabolism
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2002125618A (en) * 2000-10-30 2002-05-08 Katsuyuki Wakatsuki Health food
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
NZ573719A (en) * 2006-07-05 2011-08-26 Photonz Corp Ltd Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis
AU2010222648B2 (en) * 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
CN102458109B (en) * 2009-04-29 2015-02-11 阿马里纳制药公司 Stable pharmaceutical composition and method of using same
LT2443246T (en) * 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited COMPOSITIONS AND METHODS FOR TRIGLICERIDE REDUCTION UNDER THE LEVEL OF LDL-C WHEN USING STATIN Therapy
WO2012112531A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
JP2014505729A (en) * 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド Cholesterol absorption inhibitors (azetidinone) and omega-3 fatty acids (EPA, DHA, DPA) for the reduction of cholesterol and cardiovascular events

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014089501A1 *

Also Published As

Publication number Publication date
AU2013354979A1 (en) 2015-06-11
IN2015DE05009A (en) 2015-12-18
CN104937103A (en) 2015-09-23
CN112107570A (en) 2020-12-22
CA2894366A1 (en) 2014-06-12
MX2015007085A (en) 2016-01-12
AU2019216634A1 (en) 2019-09-05
EP2928462A2 (en) 2015-10-14
KR20150103009A (en) 2015-09-09
AU2017232203A1 (en) 2017-10-12
AU2013354969A1 (en) 2015-06-11
WO2014089511A2 (en) 2014-06-12
EP3888646A1 (en) 2021-10-06
AU2020203658A1 (en) 2020-06-25
JP2019172697A (en) 2019-10-10
EP2929041A1 (en) 2015-10-14
MX2015007082A (en) 2016-01-12
AU2021201865A1 (en) 2021-04-22
JP2016501249A (en) 2016-01-18
WO2014089501A1 (en) 2014-06-12
EP2928462A4 (en) 2016-06-01
JP2016501248A (en) 2016-01-18
JP2021120407A (en) 2021-08-19
CA2894183A1 (en) 2014-06-12
IN2015MU01505A (en) 2016-05-27
CN104902888A (en) 2015-09-09
AU2018229440A1 (en) 2018-10-04
JP6881893B2 (en) 2021-06-02
KR20210059779A (en) 2021-05-25
WO2014089511A3 (en) 2014-07-31
CN113274378A (en) 2021-08-20
KR20150103671A (en) 2015-09-11

Similar Documents

Publication Publication Date Title
FR24C1025I1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF ANEMIA
EP2934505A4 (en) EICOSAPENTAENOIC ACID FORMULATIONS (EPA)
EP2861227A4 (en) OMEGA-3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE
EP2915557A4 (en) MICRO-NEEDLE OF RETINOIC ACID
DK3072510T3 (en) Omega-3-fatty acid ester COMPOSITIONS
EP2892562A4 (en) ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE
EP2903939A4 (en) STABLE CARBOXYLIC ACID COMPOSITIONS AND USES THEREOF
EP2680886A4 (en) SUBSTITUTED QUINOLINES AND METHODS OF USE
EP2804601A4 (en) COMPOSITIONS CONTAINING PHORBOL ESTERS AND METHODS OF USING THE SAME
EP3735963C0 (en) SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACID
EP2841443A4 (en) SERPINC1 TARGET RNAI COMPOSITIONS AND METHODS OF USE
EP2603201A4 (en) LIPOSOMIC COMPOSITIONS AND METHODS OF USE
EP2812443A4 (en) ANTI-CD47 ANTIBODIES AND METHODS OF USE
EP2890772A4 (en) MULTIFUNCTIONAL COMPOSITIONS AND METHODS OF USE
EP2859111A4 (en) AMPLIFICATION OF NUCLEIC ACID
EP2596112A4 (en) ACETYLCYTEIN COMPOSITIONS AND METHODS OF USE THEREOF
EP2879677A4 (en) SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE
EP2919788A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
EP2931313A4 (en) FORMULATIONS IN SOLUTION OF MODIFIED ANTI-IL-23P19 ANTIBODIES
EP2897639A4 (en) IMPROVED VACCINE COMPOSITIONS AND METHODS OF USE
FR3015290B1 (en) HYALURONIC ACID COMPOSITIONS COMPRISING MEPIVACAINE
EP3113613A4 (en) LIPOIC ACID CHOLINE ESTER COMPOSITIONS AND METHODS OF USING SAME
EP2969012A4 (en) COMPOSITIONS AND METHODS FOR IDENTIFYING MICROBES RELATED TO SECRETORY ANTIBODIES
EP2947141A4 (en) MICROORGANISMS PRODUCING DOCOSAHEXAENOIC ACID AND THEIR USE
EP2988764A4 (en) ANTI-DANDRUFF COMPOSITIONS AND METHODS OF USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/40 20060101ALI20160429BHEP

Ipc: A61K 31/202 20060101ALI20160429BHEP

Ipc: A61K 31/225 20060101AFI20160429BHEP

Ipc: A23D 9/00 20060101ALI20160429BHEP

Ipc: C11B 5/00 20060101ALI20160429BHEP

Ipc: A61K 9/48 20060101ALI20160429BHEP

Ipc: A23D 9/06 20060101ALI20160429BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220701